batiraxcept

Batiraxcept is a recombinant fusion protein composed of the extracellular domain of the receptor tyrosine kinase AXL fused to a human immunoglobulin G1 (IgG1) Fc domain. It functions as an ultra-high affinity decoy protein that binds and sequesters growth arrest-specific 6 (GAS6), thereby preventing GAS6 from activating AXL signaling. This mechanism inhibits the GAS6/AXL pathway, which is implicated in tumor metastasis, resistance to VEGF-targeted therapies, and fibrotic processes. Batiraxcept is being developed primarily as an antineoplastic agent for cancers such as ovarian cancer, renal cell carcinoma, pancreatic cancer, and others. The drug was originally developed by Stanford University and further advanced by Aravive and its partners[1][2][3][5][8].

Brand names

batiraxcept

Other names

Axl fc fusion protein avb-s6-500